|
Concordance between PathVysion and other HER2-testing protocols |
|||||
| Comparison with PathVysion |
κ coefficient* |
Degree of agreement |
Agreement (percentage) |
Sensitivity (percentage) |
Specificity (percentage) |
|
|
|||||
| PharmDx |
1.000 |
Excellent |
100 |
100 |
100 |
| INFORM (at least six signals per nucleus) |
0.916 ± 0.058 |
Excellent |
98 |
100 |
94 |
| INFORM (at least five signals per nucleus) |
0.799 ± 0.085 |
Good |
91 |
100 |
88 |
| INFORM (more than four signals per nucleus) |
0.532 ± 0.111 |
Moderate |
76 |
100 |
57 |
| CISH (at least six signals per nucleus) |
0.876 ± 0.070 |
Excellent |
94 |
100 |
94 |
| CISH (at least five signals per nucleus) |
0.762 ± 0.091 |
Good |
89 |
100 |
88 |
| In-house IHC (positive 3+, negative 0, 1+, 2+) |
0.792 ± 0.089 |
Good |
91 |
89 |
91 |
| In-house IHC (positive 3+, 2+, negative 0, 1+) |
0.475 ± 0.111 |
Moderate |
72 |
100 |
57 |
| HercepTest (positive 3+, negative 0, 1+, 2+) |
0.645 ± 0.104 |
Good |
83 |
89 |
80 |
| HercepTest (positive 3+, 2+, negative 0, 1+) |
0.350 ± 0.119 |
Poor |
64 |
94 |
49 |
|
HER2, human epidermal growth factor receptor 2; CISH, chromogenic in situ hybridisation; IHC, immunohistochemistry. (* errors given as ± SD) | |||||
Cayre et al. Breast Cancer Research 2007 9:R64 doi:10.1186/bcr1770 |
|||||